* Panel votes 9-0 that company trial was inadequate
* FDA usually follows panel recommendations
GAITHERSBURG, Md., March 22 (Reuters) - Cell Therapeutics Inc (CTIC.O) has not collected enough data on an experimental lymphoma drug to win U.S. approval, a government advisory panel unanimously said on Monday.
Advisers to the Food and Drug Administration, in a 9-0 vote, said the company's single trial was not adequate to support approval of the drug, pixantrone.
Seattle-based Cell Therapeutics is seeking FDA clearance to sell pixantrone under the name Pixuvri for treating non-Hodgkin's lymphoma that has stopped responding to other treatments.
The final decision rests with the FDA, but the agency usually follows panel recommendations. An FDA ruling is due by April 23.
Cell Therapeutics' shares were halted on Nasdaq while the panel met. (Reporting by Lisa Richwine, editing by Maureen Bavdek)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.